Weight-loss drugs may also help cut alcohol intake: Study

A new study shows GLP-1 drugs like semaglutide may help reduce heavy drinking. A trial found weekly injections cut heavy drinking days by half. This drug, also used for obesity, showed significant results in adults with alcohol use disorder. The findings could impact millions globally. Further research is ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rw2p4TY
via IFTTT

Read More

KKR invests Rs 1,750 cr in Baby Memorial Hospital

KKR, the prominent US investment firm, has committed another ₹1,750 crore to Baby Memorial Hospital, elevating their overall investment to an impressive ₹5,100 crore in just a short span of two years. This Kozhikode-centered hospital chain is poised for significant regional growth. The capital will facilitate strategic acquisitions and further expansion, now boasting nine hospitals spread across three southern states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/neIgkx6
via IFTTT

Read More

IHH-Daiichi legal battle nears verdict on September 10

A major legal battle between IHH Healthcare and Daiichi Sankyo is reaching its climax. IHH's subsidiary, NTK, is seeking JPY 200 billion in damages. The Tokyo District Court will deliver its judgment on September 10. This ruling follows NTK's allegations of Daiichi Sankyo obstructing its acquisition of Fortis Healthcare shares.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/blz1ODJ
via IFTTT

Read More

AHH names Venkatesh Tarakkad as CFO; Ritesh Pandey moves to chief business officer role

Asia Healthcare Holdings has appointed Venkatesh Tarakkad as its new Chief Financial Officer and Head of Business Development. Tarakkad brings over three decades of experience in finance and mergers. He previously served as CFO at UpGrad. This appointment supports AHH's growth strategy. Ritesh Pandey moves to Chief Business Officer for new initiatives. AHH operates specialty healthcare brands across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JILmQ0b
via IFTTT

Read More

Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma deal

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acquisition ever by an Indian pharmaceutical company. The deal values Organon at $14 per share and gives Sun Pharma a major global expansion boost, including entry into the US women’s healthcare market and stronger presence across key international regions such as China, Europe, Korea, and Latin America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GNqISso
via IFTTT

Read More

Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution

Sun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It also offers diversification into new segments like women's health and biosimilars. The acquisition is expected to strengthen Sun Pharma's position for future growth. Managing integration and debt will be key.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVzPnCv
via IFTTT

Read More

Sun Pharma: How a small Kolkata trader became a global buyout artist

Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continues Shanghvi's proven strategy of acquiring companies to fuel growth and global expansion. His approach prioritizes strategic advantage and turnaround potential, as seen in past landmark deals like Ranbaxy and Taro.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fX9BkGL
via IFTTT

Read More